Objective: For advanced ovarian cancer patients with high perioperative risk or low likelihood of achieving optimal cytoreduction, neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) is an alternative treatment option. Furthermore, bevacizumab could consider to add in front-line ovarian cancer therapy for improving progression-free survival and increasing complete resection rate at IDS. In this study, we investigated the efficacy and feasibility of NAC with bevacizumab regimen in patients with newly diagnosed advanced ovarian cancer. Methods: We retrospectively reviewed the medical records of patients with pathologically confirmed epithelial ovarian cancer who received NAC (three cycles chemotherapy±bevacizumab) between March 2016 and February 2019. We divided the patients according to the additional use of bevacizumab in NAC and compare the response to NAC and complete resection rate at IDS. Results: We retrospectively reviewed the medical records of 110 patients who were treated with NAC followed IDS. Among them, 16 patients were treated with NAC + bevacizumab regimen. Interval from biopsy for pathologic diagnosis to IDS was 83.63±22.52 days (NAC with bevacizumab) and 81.17±18.32 days (NAC only). The complete resection rate at IDS were 56.3% (n=9, NAC with bevacizumab) and 50.0% (n=47, NAC only). When we analyzed pathologic response to NAC with chemotherapy response score (CRS), 25.0% of NAC with bevacizumab and 30.9% of NAC only group showed CRS 3 (complete or near-complete response). The PFS and OS could not show significant difference between two groups. Conclusion: In Korean patients with advanced ovarian cancer, NAC + bevacizumab followed by IDS is supposed an acceptable strategy and is expected to have clinical benefit. Although this study shown the feasibility of NAC regimen incorporating bevacizumab followed by IDS in Korean patients, further studies are needed to evaluate the prognostic impact of this strategy in real world.